Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER

Yardley, Denise A.; Tripathy, Debasish; Brufsky, Adam; Rugo, Hope S.; Kaufman, Peter A.; Mayer, Musa; Magidson, Jay; Yoo, Bongin; Quah, Cheng; Yood, Marianne Ulcickas

doi:10.1038/bjc.2014.174

Cited by 54 publications

(28 citation statements)

References 55 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As recently shown in the registHER study, a large multicenter, prospective cohort study in patients with HER2-positive metastatic breast cancer, both nonvisceral metastases (in particular, node and local sites) and hormone receptor positivity are factors associated with long-term survival [20].…”

Section: ©Alphamed Press 2015mentioning

confidence: 75%

Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study

et al. 2015

View full text Add to dashboard Cite

Background. We evaluated the patterns of care and clinical outcomes of metastatic breast cancer patientstreated with firstline trastuzumab-based therapy after previous (neo)adjuvant trastuzumab. Materials and Methods. A total of 416 consecutive, HER2-positive metastatic breast cancer patients who had received first-linetrastuzumab-basedtherapywereidentifiedat14Italian centers. A total of 113 patients had presented with de novo stage IV disease and were analyzed separately. Dichotomous clinical outcomes were analyzed using logistic regression and time-to-event outcomes using Cox proportional hazards models. Results. In the 202 trastuzumab-naïve patients and 101 patients with previous trastuzumab exposure, we observed the following outcomes, respectively: overall response rate, 69.9% versus 61.3% (adjusted odds ratio [OR], 0.62; p 5 .131), clinical benefit rate, 79.1% versus 72.5% (adjusted OR, 0.73; p 5 .370), median progression-free survival (PFS), 16.1

show abstract

Section: ©Alphamed Press 2015mentioning

confidence: 75%

Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Factors associated with longer OS included ER-or PR-positive disease, metastasis to bone only or bone plus breast or node/local sites, first-line trastuzumab use and first-line taxane use (20).…”

Section: Prognostic and Predictive Factors On Anti-her2 Treatmentmentioning

confidence: 99%

Long‑responders to anti‑HER2 therapies: Aï¿½caseï¿½report and review of the literature

et al. 2017

View full text Add to dashboard Cite

“…[4, 8] It has been recently reported that 25–30% of patients with HER2-positive MBC survived five or more years following treatment with HER2-targeted therapy. [9, 10]…”

Section: Introductionmentioning

confidence: 99%

Clinical predictors of long-term survival in HER2-positive metastatic breast cancer

Murthy

Kidwell

Schott

et al. 2016

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose Prior to availability of anti-HER2 therapies, HER2-positive metastatic breast cancer (MBC) was associated with a poor prognosis. Prospective randomized trials have demonstrated survival benefit from anti-HER2 treatments. Anecdotal observations have suggested that a small but meaningful fraction of patients with HER2-positive MBC may be “exceptional responders” with long survival. We hypothesized that demographic and/or clinicopathologic characteristics can be identified to distinguish short-term from long-term survivors. Methods A retrospective, single institution review of 168 patients with HER2-positive MBC who received treatment with anti-HER2 therapy in the metastatic setting was performed. Cox proportional hazards analysis was used to assess factors associated with long-term survival. Results Median overall survival from the time of breast cancer recurrence was 3.9 years (95% CI 3.4–5.2). From the time of diagnosis of MBC, 56 (33%) survived for 5 or more years and 12 (7%) survived more than 10 years. Of the 66 patients diagnosed with central nervous system metastases, 9 (14%) survived more than 5 years following that diagnosis. Younger age at diagnosis, lower stage, hormone receptor positive status, and only having one organ involved at diagnosis were associated with longer survival. Four patients discontinued anti-HER2 therapy and are without evidence of progression of disease after a median 7.4 years (0.2–12.0) since stopping therapy. Conclusions In a cohort of patients with HER2-positive MBC treated primarily with trastuzumab and lapatinib, 7% of patients were “exceptional responders”. Combining these clinical factors associated with molecular determinants of prolonged survival with may provide insights for individualizing treatment selection.

show abstract

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER

Cited by 54 publications

References 55 publications

Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study

Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study

Long‑responders to anti‑HER2 therapies: Aï¿½caseï¿½report and review of the literature

Clinical predictors of long-term survival in HER2-positive metastatic breast cancer

Contact Info

Product

Resources

About